RecruitingPhase 2NCT05884866

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

Natriuretic-ureothelic Adaptation of Body Fluid Homeostasis During SGLT-2 Inhibition and/or Mineralocorticoid Receptor Modulation in Patients With Chronic Kidney Disease. A 4-arm, Double-blind, Double-dummy, Parallel-group, Phase 2 Study to Investigate the Mechanistic Effects of Dapagliflozin, Dapagliflozin + Balcinrenone, Balcinrenone and Placebo on Body Solute and Water Homeostasis and Energy Metabolism in Male and Female Participants Over 50 Years of Age With Chronic Kidney Disease.


Sponsor

Klinikum Nürnberg

Enrollment

100 participants

Start Date

Jul 13, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to investigate the mechanistic effects of dapagliflozin 10 mg, alone or in combination with balcinrenone 150 mg, with balcinrenone 150 mg and placebo, on the way the body handles electrolytes and water content, as well as the effects these interventions may have on energy metabolism in participants with stage 3 chronic kidney disease. The study interventions will be administered orally, daily, in addition to current therapy, for a duration of 28 days. This will allow us to maximize our ability to detect a drug effect while minimizing the drop-out rate that accompanies longer studies. In order to understand the different mechanistic effects of these interventions on energy metabolism, the study will be conducted at two study sites. The study design and treatment allocation, treatment duration as well as sample analysis for evaluation of the primary endpoint will be identical for all participants, at both sites. Therefore, urine and plasma samples for analysis of water and electrolyte handling will be collected from all study participants at both sites. In addition to the primary endpoint, the main study site (Nuremberg) will conduct a metabolic study to investigate the early- and late-effects of the interventions, while the second site, Marseille, will conduct an imaging sub-study to assess changes at the tissue level before and after treatment.


Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how two medications — dapagliflozin (a diabetes/kidney drug) and balcinrenone (a newer hormone-blocking drug) — affect fluid balance, salt levels, and energy metabolism in people with moderate chronic kidney disease (CKD). **You may be eligible if...** - You have been diagnosed with chronic kidney disease with a kidney function (eGFR) between 30 and 60 - Your blood potassium and sodium levels are within normal ranges - You are over 50 years old - Your medications have been stable for at least 3 weeks before starting the study - If you have type 2 diabetes, you may be on certain oral diabetes medications **You may NOT be eligible if...** - You are on dialysis or have very advanced kidney failure - You have serious heart failure or liver disease - You are pregnant or planning to become pregnant - You have a known allergy to dapagliflozin or similar drugs - Your potassium is too high or too low Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDapagliflozin 10mg Tab

see arms

DRUGBalcinrenone 50mg Capsule

see arms

DRUGBalcinrenone 100mg Capsule

see arms

DRUGDapagliflozin matching Placebo

see arms

DRUGBalcinrenone 50mg matching Placebo

see arms

DRUGBalcinrenone 100mg matching Placebo

see arms


Locations(2)

Assistance Publique-Hopitaux de Marseille (AP-HM)

Marseille, France

Klinikum Nuernberg

Nuremberg, Bavaria, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05884866


Related Trials